0001209191-12-014562.txt : 20120301 0001209191-12-014562.hdr.sgml : 20120301 20120301170841 ACCESSION NUMBER: 0001209191-12-014562 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20120228 FILED AS OF DATE: 20120301 DATE AS OF CHANGE: 20120301 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: DERBYSHIRE ADAM C CENTRAL INDEX KEY: 0001212669 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-23265 FILM NUMBER: 12658783 MAIL ADDRESS: STREET 1: 8540 COLONNADE CENTER DRIVE STREET 2: SUITE 501 CITY: RALEIGH STATE: NC ZIP: 27615 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SALIX PHARMACEUTICALS LTD CENTRAL INDEX KEY: 0001009356 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943267443 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 8510 COLONNADE CENTER DRIVE CITY: RALEIGH STATE: NC ZIP: 27615 BUSINESS PHONE: (919) 862-1000 MAIL ADDRESS: STREET 1: 8510 COLONNADE CENTER DRIVE CITY: RALEIGH STATE: NC ZIP: 27615 FORMER COMPANY: FORMER CONFORMED NAME: SALIX HOLDINGS LTD DATE OF NAME CHANGE: 19970807 4 1 doc4.xml FORM 4 SUBMISSION X0304 4 2012-02-28 0 0001009356 SALIX PHARMACEUTICALS LTD SLXP 0001212669 DERBYSHIRE ADAM C 8510 COLONNADE CENTER DRIVE RALEIGH NC 27615 0 1 0 0 EVP Finance/CFO Common Stock 2012-02-28 4 M 0 12600 4.0666 A 143738 D Common Stock 2012-02-28 4 S 0 12600 50.09 D 131138 D Option to Buy Common Stock 4.0666 2012-02-28 4 M 0 12600 0.00 D 2012-07-02 Common Stock 12600 0 D Option to Buy Common Stock 17.63 2015-06-09 Common Stock 20000 20000 D Option to Buy Common Stock 18.8733 2014-06-17 Common Stock 30000 30000 D Option to Buy Common Stock 8.00 2013-05-30 Common Stock 90000 90000 D The shares covered by this Form 4 have been sold pursuant to a Rule 10b5-1 Sales Plan dated December 2, 2011, which is intended to comply with Rule 10b5-1. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.00 to $50.34, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Options are 100% vested. /s/ Donald R. Reynolds, by Power of Attorney 2012-03-01